Search results for "Bone Density Conservation Agent"

showing 5 items of 105 documents

Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review

2018

Abstract Purpose Bisphosphonate therapy is a well-established and effective treatment for postmenopausal osteoporosis and the prevention of osteoporotic fracture. However, poor adherence to and poor persistence with bisphosphonate therapy may reduce its benefits. Previous studies have documented the poor rates of adherence and persistence among postmenopausal women with osteoporosis. The objective of this systematic literature review was to evaluate adherence, persistence, and the impact of adherence and persistence on fracture risk in postmenopausal women with diagnosed osteoporosis. Methods Articles eligible for review included observational studies of the real-world use of bisphosphonate…

medicine.medical_specialtymedicine.medical_treatmentOsteoporosisMEDLINE02 engineering and technology030204 cardiovascular system & hematologyMedication AdherencePersistence (computer science)03 medical and health sciences020210 optoelectronics & photonics0302 clinical medicineInternal medicine0202 electrical engineering electronic engineering information engineeringmedicineHumansPharmacology (medical)Osteoporosis PostmenopausalPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryBisphosphonatemedicine.diseasePostmenopauseMenopauseObservational Studies as TopicTreatment OutcomeSystematic reviewFemaleObservational studybusinessOsteoporotic FracturesBiomedical sciencesClinical Therapeutics
researchProduct

Proposal for a preventive protocol for medication-related osteonecrosis of the jaw.

2021

Background Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some patients exposed to certain drugs (antiresorptives such as bisphosphonates or denosumab, and antiangiogenic drugs). From a review of the literature it appears that there is no uniform criterion when selecting preventive measures; these vary according to author. Likewise, the measures recommended are usually general, so that in few cases they result in specific actions to be applied depending on the different variables involved such as the type of drug used, the duration of its application, the underlying pathology, the presence or absence of risk factors, etc. The aim of this stud…

medicine.medical_specialtymedicine.medical_treatmentOsteoporosisMEDLINEReviewsleep disturbancesolder people03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectDental implantGeneral DentistryUNESCO:CIENCIAS MÉDICASProtocol (science)dental implantOral Medicine and PathologyedentulismBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosis030206 dentistrymedicine.diseaseDenosumabSystematic reviewOtorhinolaryngologyOsteoporosisSurgeryBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo

2012

Abstract Introduction Bisphosphonates are important and effective drugs in oncology and osteoporosis therapy. They accumulate in the bone matrix becoming released and active by bone resorption. This leads to effective inhibition of tumor cells and bone degradation. A side effect of bisphosphonates similar to other drugs like denosumab is osteonecrosis of the jaws (ONJ). This problem mostly occurs after tooth extraction. We studied the cytoprotectant dexrazoxane known from anthracycline chemotherapy for cytoprotection in nitrogen-containing bisphosphonate treated cells and in the rabbit tibia model to evaluate a possible value in ONJ management. Materials & methods Human osteoblasts (HOB) P2…

medicine.medical_treatmentOsteoporosisCell Culture TechniquesGingivaTetrazolium SaltsApoptosisPharmacologyCell morphologyZoledronic AcidOsteogenesisColoring AgentsDrug CarriersBone Density Conservation AgentsDiphosphonatesImidazolesFluoresceinsResorptionDenosumabModels AnimalFemaleCollagenRabbitsOral SurgeryRazoxanemedicine.drugmedicine.medical_specialtyCell SurvivalProtective AgentsBone resorptionCell LinemedicineAnimalsHumansBone ResorptionCell ShapeFluorescent DyesOsteoblastsTibiabusiness.industryFibroblastsBisphosphonatemedicine.diseaseSurgeryThiazolesDurapatiteZoledronic acidOtorhinolaryngologyCytoprotectionSurgeryDexrazoxanebusinessJournal of Cranio-Maxillofacial Surgery
researchProduct

Silicate modulates the cross-talk between osteoblasts (SaOS-2) and osteoclasts (RAW 264.7 cells): inhibition of osteoclast growth and differentiation

2012

It has been shown that inorganic monomeric and polymeric silica/silicate, in the presence of the biomineralization cocktail, increases the expression of osteoprotegerin (OPG) in osteogenic SaOS-2 sarcoma cells in vitro. In contrast, silicate does not affect the steady-state gene expression level of the osteoclastogenic ligand receptor activator of NF-κB ligand (RANKL). In turn it can be expected that the concentration ratio of the mediators OPG/RANKL increases in the presence of silicate. In addition, silicate enhances the growth potential of SaOS-2 cells in vitro, while it causes no effect on RAW 264.7 cells within a concentration range of 10-100 µM. Applying a co-cultivation assay system,…

musculoskeletal diseasesCell SurvivalCellular differentiationmedicine.medical_treatmentAcid PhosphataseMineralogyOsteoclastsCell Count02 engineering and technologyCell CommunicationBiochemistryCell Line03 medical and health sciencesMiceOsteoprotegerinOsteoclastOsteogenesismedicineAnimalsHumansMolecular BiologyRAW 264.7 Cells030304 developmental biologyTartrate-resistant acid phosphataseCell Proliferation0303 health sciencesOsteoblastsbiologyBone Density Conservation AgentsChemistryTartrate-Resistant Acid PhosphataseMacrophagesSilicatesRANK LigandCell DifferentiationCell Biology021001 nanoscience & nanotechnologyCoculture TechniquesCell biologyIsoenzymesmedicine.anatomical_structureCytokineCell cultureRANKLbiology.protein0210 nano-technologyJ. Cell. Biochem.
researchProduct

Successful treatment of primary chronic osteomyelitis in SAPHO syndrome with bisphosphonates.

2008

Summary The treatment of the painful osteomyelitis in patients with SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) is often a problem. A 53-year-old woman had experienced palmo-plantar pustular skin lesions for four years, and in the past two years complained about progressive breath-and movement-dependent pain of the sternum. On examination she had extensive palmoplantar pustules and a painful swelling in the area of the right sternoclavicular joint. The three-phase bone scintigraphy showed a strong focal enrichment in the right sternoclavicular joint and at the transition from the manubrium to the corpus sterni suggesting active osteo-chondritis. Initially prednisolo…

musculoskeletal diseasesSAPHO syndromemedicine.medical_specialtyHyperostosisDermatologySynovitismedicineHumansAcnemedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteomyelitisAcquired Hyperostosis SyndromeOsteomyelitisMiddle Agedmedicine.diseasePustulosisDermatologySurgeryTreatment OutcomeBone scintigraphyChronic DiseaseFemaleOsteitismedicine.symptombusinessJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct